Commentary: Outcome measures were flawed

BMJ (Online)

Volumn 340, Issue 7759, 2010, Pages 1286-

  Ebers, G C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON;

DISABILITY; DISEASE COURSE; DRUG COST; FOLLOW UP; HEALTH CARE COST; HUMAN; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE;

COST-BENEFIT ANALYSIS; DATA COLLECTION; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERFERONS; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; RISK SHARING, FINANCIAL;

EID: 77953698223     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c2693     Document Type: Note

References (14)

1. INFB MS study group. Interferon beta-Ib is effective in relapsing/remitting multiple sclerosis: I. Clinical results of a multicenter randomized trial. Neurology 1993;43:655-61.[Abstract/Free Full Text]
2. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Results from a 3-year controlled study. Neurology 2004;63:1788-95. [Abstract/Free Full Text]
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94. [CrossRef][Web of Science][Medline]
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copoplymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995:43:1268-76.
5. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology 2008;71:624-31.[Abstract/Free Full Text]
6. Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke expanded disability status scale (EDSS). Neurology 1992;42:859-63. [Abstract/Free Full Text]
7. Daumer M, Neuhaus A, Morrissey S, Hintzen F, Ebers GC. Magnetic resonance imaging as an outcome in MS clinical trials. Neurology 2009;72:705-11. [Abstract/Free Full Text]
8. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989;112:1419-28.[Abstract/Free Full Text]
9. Ebers GC. Preventing multiple sclerosis? Lancet 2001;357:1547.[CrossRef] [Web of Science][Medline]
10. Filippini G, Munari L, Incorvaia B, Ebers G, Polman C, Amico R, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-52.[CrossRef][Web of Science][Medline]
11. Kappos L, Traboulsee A, Constantinescu C, Erälinna J, Forrestal JF, Jongen P, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53.[Abstract/Free Full Text] (Pubitemid 44454583)
12. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Multiple Sclerosis 2010;16:342-50. [Abstract/Free Full Text]
13. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin D, et al. Long-term follow up of the original interferon-ß1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009;31:1724-36.[CrossRef][Web of Science][Medline]
14. Boggild M, Palace J, Barton P, Ben-Schlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677.[Abstract/Free Full Text]